Dual p38MAPK and MEK inhibition disrupts adaptive chemoresistance in mesenchymal glioblastoma to temozolomide.

Hong Sheng ChengYuk Kien ChongEldeen Kai Yi LimXin Yi LeeQing You PangWisna NoveraCharlie MarvalimJeannie Xue Ting LeeBeng Ti AngCarol TangNguan Soon Tan

Published in: Neuro-oncology (2024)

Temozolomide resistance in mesenchymal glioblastoma is associated with p38MAPK activation. Adaptive chemoresistance in p38MAPK-resistant cells is mediated by MEK/ERK signaling. Adjuvant therapy with dual p38MAPK and MEK inhibition prolongs temozolomide sensitivity, which can be developed into a precision therapy for the mesenchymal subtype.

Keyphrases

pi k akt
cell cycle arrest
bone marrow
stem cells
signaling pathway
induced apoptosis
newly diagnosed
cell proliferation
oxidative stress
endoplasmic reticulum stress
cancer stem cells